
Ugur Sahin
Patrimonio netto: 3 845 M $ in data 31/05/2026

Patrimonio netto: 3 845 M $ in data 31/05/2026
Fondatore di BioNTech SE, Ganymed Pharmaceuticals AG, Ci3 Management UG e TRON - Translationale Onkologie an der Universittsmedizin der, Ugur Sahin è attualmente Chief Executive Officer di BioNTech SE e Managing Director di reBOOST Management GmbH (una filiale di BioNTech SE) e Managing Director di Medine GmbH. Il Dr. Sahin è anche professore alla Universittsmedizin der Johannes Gutenberg-Universitt Mainz. In precedenza ha occupato la posizione di Chief Medical Officer per Ganymed Pharmaceuticals AG e di Co-Managing Director presso TRON - Translationale Onkologie an der Universittsmedizin der. Il Dr. Sahin ha ricevuto un dottorato dalla Universitt zu Kln.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
BIONTECH SE 16,59% | 31/03/2026 | 40.076.320 ( 16,59% ) | 3 845 M $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| BIONTECH SE | Amministratore Delegato | 02/06/2008 |
reBOOST Management GmbH
reBOOST Management GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Amministratore Delegato | 23/10/2018 |
Medine GmbH
Medine GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Amministratore Delegato | 14/03/2011 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Medical/Nursing ServicesHealth Services Provides health care facilities and services | Corporate Officer/Principal | 01/01/2014 |
Helmholtz Institute For Translational Oncology | Corporate Officer/Principal | - |
BioNTech Delivery Technologies GmbH
BioNTech Delivery Technologies GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of immunotherapies | Amministratore Delegato | - |
| Società | Posizione | Fine |
|---|---|---|
TRON - Translationale Onkologie an der Universitätsmedizin der
TRON - Translationale Onkologie an der Universitätsmedizin der Miscellaneous Commercial ServicesCommercial Services Operates as biopharmaceutical research organization | Amministratore Delegato | 01/01/2019 |
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Develops antibodies for the treatment of solid cancers | Fondatore | 30/07/2010 |
Ci3 Management UG | Fondatore | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Develops antibodies for the treatment of solid cancers | Health Technology |
Universität zu Köln
Universität zu Köln Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNTech SE
BioNTech SE BiotechnologyHealth Technology Develops immunotherapies and mRNA-based vaccines to treat cancer & infectious diseases | Health Technology |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Medical/Nursing ServicesHealth Services Provides health care facilities and services | Health Services |
Ci3 Management UG | |
TRON - Translationale Onkologie an der Universitätsmedizin der
TRON - Translationale Onkologie an der Universitätsmedizin der Miscellaneous Commercial ServicesCommercial Services Operates as biopharmaceutical research organization | Commercial Services |
Medine GmbH
Medine GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Commercial Services |
reBOOST Management GmbH
reBOOST Management GmbH Miscellaneous Commercial ServicesCommercial Services Provides management consultancy services | Commercial Services |
BioNTech Delivery Technologies GmbH
BioNTech Delivery Technologies GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of immunotherapies | Commercial Services |
Helmholtz Institute For Translational Oncology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale